

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN

VONICOG ALFA

PRONUNCIATION

voe' ni kog al' fa

THERAPEUTIC CLAIM

Prophylactic treatment of bleeding episodes and Von Willebrand disease

CHEMICAL NAMES

1. Blood-coagulation factor VIII, von Willebrand's
2. [618-threonine,709-aspartic acid]von Willebrand factor *Homo sapiens* (1381A>T,1472H>D variant)

STRUCTURAL FORMULA

Monomer / Monomère / Monómero

SLSCRPPMVK	LVCPADNLRA	EGLECTKTCQ	NYDLECMSMG	CVSGCLCPPG	50
MVRHENRCVA	LERPCPFHQG	KEYAPGETVK	IGCNTCVCRD	RKWNCTDHVC	100
DATCSTIGMA	HYLTFDFGLKY	LFPGECQYVL	VQDYCGSNPG	TFRLLVGNKG	150
CSHPSVKCKK	RVTILVEGGE	IELFDGEVNV	KRPMKDETHF	EVVESGRYII	200
LLLGKALSVV	WRHLSISVV	LKQTYQEKVC	GLCGNFDGIQ	NNDLTSSNLQ	250
VEEDPVDVFN	SWKVSSQCAD	TRKVPDSSP	ATCHNNIMKQ	TMVDSSCRIL	300
TSDVFDQCNK	LVDPEPYLDV	CIYDTCSCES	IGDCACFCDT	IAAYAHVCAQ	350
HGKVVTWRTA	TLCPQSCER	NLRENGYECE	WRYNSCAPAC	QVTCQHPEPL	400
ACPVQCVEGC	HAHCPPGKIL	DELLQTCVDP	EDCPVCEVAG	RRFASGKKVT	450
LNPSPDPEHCQ	ICHCDVNNLT	CEACQEPGGL	VVPPDAPVS	PTTLYVEDIS	500
EPLLHDFYCS	RLLDLVLFLD	GSSRLSEAEF	EVLKAFVVDM	MERLRISQKW	550
VRVAVVEYHD	GSHAYIGLKD	RKRPSSELRI	ASQVKYAGSQ	VASTSEVLKY	600
TLFQIFSKID	REASRITLL	LMASQEPQRM	SRNFVRYVQG	LKKKVVIVIP	650
VGIGPHANLK	QIRLIEKQAP	ENKAFVLSSV	DELEQQRDEI	VSYLCDLAPE	700
APPPTLPPDM	GVTVVGPGLL	GVSTLGPKRN	SMVLDVAFVL	EGSDKIGEAD	750
FNRSKEFMEE	VIQRMDVGQD	SIHVTVLQYS	YMTVEYPPFS	EAQSKGDILQ	800
RVREIRYQGG	NRTNTGLALR	YLSHHSFLVS	QGDRQAPNL	VYMTGNPAS	850
DEIKRLPGDI	QVVPVIGVGN	ANVQELERIG	WPNAPILIQD	FETLPREAPD	900
LVLQRCCSGE	GLQIPTLSPA	PDCSQPLDVI	LLLDGSSSFP	ASYFDEMKSF	950
AKAFISKANI	GPRLTQVSVL	QYGSITIDV	PWNVVPEKAH	LLSLVDVMQR	1000
EGGPSQIGDA	LGFAVRYLTS	EMHGARPGAS	KAVVILVTDV	SVDSVDAAAD	1050
AARSNRVTVF	PIGIGDRYDA	AQLRILAGPA	GDSNVVKLQR	IEDLPTMVTL	1100
GNSFLHKLCS	GFVVICMDED	GNEKRPGDVW	TLPDQCHTVT	CQPDGQTLK	1150
SHRVNCDRGL	RPSCPNSQSP	VKVEETCGCR	WTCPCVCTGS	STRHIVTFDG	1200
QNFKLTGSCS	YVLFQNKQD	LEVILHNGAC	SPGARQGCМК	SIEVKHSALS	1250
VELHSDMEVT	VNGLRVSVPY	VGGNMEVNVY	GAIMHEVRFN	HLGHIFTFTP	1300
QNNEFQLQLS	PKTFASKTYG	LCGICDENGА	NDFMLRDGTV	TTDWKTLVQE	1350
WTVQRPQGTC	QPILQEQCLV	PDSSHCQVLL	LPLFAECHKV	LAPATFYAIC	1400
QQDSCHQEQV	CEVIASYAHL	CRTNGVCVDW	RTPDFCAMSC	PPSLVYNHCE	1450
HGCPRHCDGN	VSSCGDHPSE	GCFCPPDKVM	LEGSCVPPEA	CTQCIGEDGV	1500
QHQFLEAWVP	DHQPCQICTC	LSGRKVNCTT	QPCPTAKAPT	CGLCEVARLR	1550
QNADQCCPEY	ECVCDPVSCD	LPPVPHCERG	LQPTLTNPGE	CRPNFTCACR	1600
KEECKRVSP	SCPPHRLPTL	RKTQCCEYE	CACNCVNSTV	SCPLGYLAST	1650
ATNDCGCTTT	TCLPDKVCVH	RSTIYPVQGF	WEEGCDVCTC	TMEDAVMGL	1700
RVAQCSQKPC	EDSCRSGFTY	VLHEGECGR	CLPSACEVVT	GSPRGDSQSS	1750
WKSVMGQWAS	PENPCLINEC	VRVKEEVFIQ	QRNVSCPQLE	VPVCPSGFQL	1800
SCKTSACCPS	CRCERMEACM	LNQTVIGPGK	TVMIDVCTTC	RCMVQGVVIS	1850
GFKLECRKTT	CNPCPLGYKE	ENNTGECGR	CLPTACTIQL	RGGQIMTLKR	1900
DETLQDGCDT	HFCKVNERGE	YFWEKRVTC	PPFDEHKCLA	EGGKIMKIPG	1950
TCCDTCEPE	CNDIARTLQY	VKVGSKSEV	EVDIHYCQGK	CASKAMYSID	2000
INDVQDQCS	CSPTRTFPMQ	VALHCTNGSV	VYHEVLNAME	CKCSPRKCSK	2050

MOLECULAR FORMULA

$C_{9712}H_{15373}N_{2737}O_{3032}S_{210}$

MOLECULAR WEIGHT

225.7 kDa

TRADEMARK

None as yet

SPONSOR

Baxter Healthcare Corporation

CODE DESIGNATION

BAX 111

CAS REGISTRY NUMBER

109319-16-6